Cancer / Oncology
Compounds
catalog compound
Metformin
Modest complex I inhibition raises AMP:ATP, activating and restraining hepatic and -linked anabolism. Direct antineoplastic efficacy is not established from that pharmacology alone.
Mapped cancers: Breast cancer, ER+ breast cancer, PR+ breast cancer, HER2+ breast cancer, Triple-negative breast cancer, Lung cancer, Non-small-cell lung cancer, Small-cell lung cancer, EGFR-mutant NSCLC, ALK-rearranged NSCLC, KRAS-driven NSCLC, ROS1-rearranged NSCLC, MET-altered NSCLC, RET-rearranged NSCLC, BRAF-mutant NSCLC, Mesothelioma, Colorectal cancer, MSS colorectal cancer, KRAS-mutant colorectal cancer, BRAF-mutant colorectal cancer, HER2-amplified colorectal cancer, Pancreatic cancer, Gastric cancer, Esophageal cancer, Hepatocellular carcinoma, Liver cancer, Cholangiocarcinoma, Ovarian cancer, Cervical cancer, Endometrial cancer, Uterine cancer, Prostate cancer, Androgen-sensitive prostate cancer, Castration-resistant prostate cancer, Kidney / renal cell carcinoma, Bladder cancer, Leukemias, Acute myeloid leukemia, Acute lymphoblastic leukemia, Non-Hodgkin lymphoma, Multiple myeloma, Brain tumors, Glioblastoma, IDH-mutant glioma, IDH-wildtype glioma, Melanoma, NRAS-driven melanoma, Head and neck cancers, Thyroid cancer, Neuroendocrine tumors, Sarcomas, Bone cancers
catalog compound
Tamoxifen
Selective estrogen- modulator that antagonizes ERα-driven in breast epithelium while retaining partial activity in some other tissues.
Mapped cancers: Breast cancer, ER+ breast cancer, PR+ breast cancer
catalog compound
Mebendazole
Benzimidazole that binds β-. Mammalian disruption, mitotic arrest and related signalling in cancer models are preclinical and are not an approved anticancer use.
Mapped cancers: Breast cancer, HER2+ breast cancer, Triple-negative breast cancer, Lung cancer, Non-small-cell lung cancer, Small-cell lung cancer, EGFR-mutant NSCLC, ALK-rearranged NSCLC, Colorectal cancer, Pancreatic cancer, Gastric cancer, Ovarian cancer, Prostate cancer, Castration-resistant prostate cancer, Neuroendocrine prostate cancer, Bladder cancer, Testicular cancer, Leukemias, Acute myeloid leukemia, Acute lymphoblastic leukemia, Non-Hodgkin lymphoma, Brain tumors, Glioblastoma, IDH-mutant glioma, IDH-wildtype glioma, MGMT-methylated glioma, Melanoma, KIT-associated melanoma, Head and neck cancers, Neuroendocrine tumors, Sarcomas, Bone cancers
catalog compound
Fenbendazole
Veterinary benzimidazole with and experimental glucose-transport effects in cell models. Not an established human antineoplastic.
Mapped cancers: Triple-negative breast cancer, Glioblastoma
catalog compound
Albendazole
Benzimidazole anthelmintic with effects; mammalian oncology readouts remain preclinical.
Mapped cancers: none yet
catalog compound
Niclosamide
uncoupler in cestodes; mammalian models report , Wnt/β-catenin and modulation. Those host-signalling findings are investigational/preclinical.
Mapped cancers: Triple-negative breast cancer, Small-cell lung cancer, Colorectal cancer, MSS colorectal cancer, KRAS-mutant colorectal cancer, APC-driven colorectal cancer, Pancreatic cancer, Gastric cancer, Hepatocellular carcinoma, Ovarian cancer, Prostate cancer, Castration-resistant prostate cancer, Neuroendocrine prostate cancer, Glioblastoma
catalog compound
Ivermectin
Glutamate-gated chloride channel in invertebrates. Reported mammalian effects on nuclear transport and signalling pathways come from experimental systems and do not constitute proven anticancer therapy.
Mapped cancers: none yet
catalog compound
Hydroxychloroquine
Lysosomotropic agent that raises endosomal/autophagosomal pH, impairing flux. Combination trials in oncology have been mixed; blockade is not equivalent to proven benefit.
Mapped cancers: Breast cancer, Triple-negative breast cancer, Non-small-cell lung cancer, Small-cell lung cancer, EGFR-mutant NSCLC, Pancreatic cancer, Ovarian cancer, Neuroendocrine prostate cancer, Acute myeloid leukemia, Non-Hodgkin lymphoma, Multiple myeloma, Glioblastoma, IDH-wildtype glioma, MGMT-methylated glioma, Melanoma, BRAF-driven melanoma, Neuroendocrine tumors
catalog compound
Itraconazole
Azole antifungal; off-target reports include Hedgehog-pathway antagonism and anti-angiogenic endothelial effects in experimental and early clinical settings. Not a licensed antineoplastic.
Mapped cancers: Lung cancer, Non-small-cell lung cancer, Mesothelioma, Gastric cancer, Hepatocellular carcinoma, Cholangiocarcinoma, Ovarian cancer, Prostate cancer, Castration-resistant prostate cancer, Kidney / renal cell carcinoma, Glioblastoma, KIT-associated melanoma, Skin cancers, Head and neck cancers, Neuroendocrine tumors, Sarcomas
catalog compound
Doxycycline
Tetracycline antibiotic that can inhibit matrix metalloproteinases and, at experimental exposures, protein synthesis. Oncology uses remain investigational.
Mapped cancers: Triple-negative breast cancer, Non-small-cell lung cancer, MET-altered NSCLC, Pancreatic cancer, Multiple myeloma, Glioblastoma, Sarcomas, Bone cancers
catalog compound
Azithromycin
Macrolide with immunomodulatory properties and experimental / observations. Not an anticancer indication.
Mapped cancers: none yet
catalog compound
Nitazoxanide
Antiparasitic interfering with PFOR in anaerobes. Broader in-vitro reports include metabolic and -related readouts; these are not clinical oncology indications.
Mapped cancers: none yet
catalog compound
Melatonin
MT1/MT2 circadian with antioxidant chemistry. Adjunctive oncology hypotheses exist; circadian and redox effects should not be read as anticancer proof.
Mapped cancers: Breast cancer
catalog compound
N-acetylcysteine
Cysteine donor replenishing glutathione. Redox buffering can be protective or, in some models, support tumour antioxidant capacity. Dual-edged; not an antineoplastic.
Mapped cancers: Triple-negative breast cancer
catalog compound
AICAR
AMP mimetic that activates in experimental systems. Research tool, not an approved oncology medicine.
Mapped cancers: Triple-negative breast cancer
repurposed pharmaceutical
Statins (HMG-CoA reductase inhibitors)
Inhibit HMG-CoA reductase, depleting mevalonate-pathway isoprenoids needed for RAS/RHO prenylation and some sterol-dependent growth programmes. Observational oncology signals are mixed and not a licence to treat cancer with statins.
Mapped cancers: Breast cancer, ER+ breast cancer, Lung cancer, Non-small-cell lung cancer, KRAS-driven NSCLC, BRAF-mutant NSCLC, Colorectal cancer, KRAS-mutant colorectal cancer, BRAF-mutant colorectal cancer, Hepatocellular carcinoma, Endometrial cancer, Prostate cancer, Androgen-sensitive prostate cancer, Castration-resistant prostate cancer, Melanoma, BRAF-driven melanoma, NRAS-driven melanoma, Thyroid cancer
repurposed pharmaceutical
Celecoxib
Selective -2 reducing PGE2. Relevant to -associated epithelial neoplasia; cardiovascular risk and lack of broad anticancer approval constrain interpretation.
Mapped cancers: Breast cancer, ER+ breast cancer, Mesothelioma, Colorectal cancer, MSI-high colorectal cancer, MSS colorectal cancer, BRAF-mutant colorectal cancer, APC-driven colorectal cancer, Gastric cancer, Esophageal cancer, Hepatocellular carcinoma, Cervical cancer, Endometrial cancer, Prostate cancer, Bladder cancer, Hodgkin lymphoma, Skin cancers, Head and neck cancers, Thyroid cancer
repurposed pharmaceutical
Disulfiram
ALDH ; copper-complexed forms can inhibit proteasome and NF-κB-related survival programmes in models. Clinical oncology evidence remains limited.
Mapped cancers: Triple-negative breast cancer, Small-cell lung cancer, Pancreatic cancer, Ovarian cancer, Neuroendocrine prostate cancer, Testicular cancer, Acute myeloid leukemia, Non-Hodgkin lymphoma, Multiple myeloma, Glioblastoma, MGMT-methylated glioma, Bone cancers
repurposed pharmaceutical
Propranolol
Non-selective β-adrenergic . Adrenergic signalling can support and invasion in some tumours; selected clinical experiences (e.g. infantile haemangioma is established vascular biology, oncology uses are a different question).
Mapped cancers: Breast cancer, Kidney / renal cell carcinoma, Melanoma, BRAF-driven melanoma, NRAS-driven melanoma, Sarcomas
repurposed pharmaceutical
Losartan
AT1- . In desmoplastic models, angiotensin blockade can reduce TGF-β-linked stromal compression and improve perfusion; this is adjunctive stromal biology, not cytotoxic oncology.
Mapped cancers: Mesothelioma, MSS colorectal cancer, Pancreatic cancer, Cholangiocarcinoma
repurposed pharmaceutical
Candesartan
ARBs share AT1-blockade biology with losartan. Tumour- hypotheses are class-level and not tumour-type-proven treatments.
Mapped cancers: Pancreatic cancer
nutraceutical
Curcumin
Polyphenol with promiscuous in-vitro NF-κB, and ROS effects. Bioavailability is poor; dish activity does not establish clinical anticancer efficacy.
Mapped cancers: Breast cancer, HER2+ breast cancer, Triple-negative breast cancer, Lung cancer, Non-small-cell lung cancer, Mesothelioma, Colorectal cancer, MSI-high colorectal cancer, MSS colorectal cancer, APC-driven colorectal cancer, Pancreatic cancer, Gastric cancer, Esophageal cancer, Hepatocellular carcinoma, Liver cancer, Cholangiocarcinoma, Ovarian cancer, Cervical cancer, Endometrial cancer, Prostate cancer, Kidney / renal cell carcinoma, Bladder cancer, Leukemias, Acute myeloid leukemia, Acute lymphoblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, Multiple myeloma, Glioblastoma, Melanoma, Skin cancers, Head and neck cancers
nutraceutical
Sulforaphane
Isothiocyanate that can activate NRF2 via KEAP1 modification and has epigenetic HDAC-related reports in models. Chemoprevention hypotheses exceed proven oncology treatment.
Mapped cancers: Lung cancer, Non-small-cell lung cancer, KRAS-driven NSCLC, Colorectal cancer, Kidney / renal cell carcinoma
nutraceutical
EGCG
Green-tea catechin with in-vitro effects on RTKs, epigenetic enzymes and redox. Clinical anticancer efficacy is not established.
Mapped cancers: Breast cancer, HER2+ breast cancer, Lung cancer, EGFR-mutant NSCLC, Colorectal cancer, HER2-amplified colorectal cancer, Esophageal cancer, Cervical cancer, Bladder cancer, Head and neck cancers
nutraceutical
Berberine
Isoquinoline alkaloid that can inhibit complex I and activate in metabolic models, with additional -independent reports. Not an approved antineoplastic.
Mapped cancers: Breast cancer, ER+ breast cancer, KRAS-driven NSCLC, Colorectal cancer, Pancreatic cancer, Hepatocellular carcinoma, Endometrial cancer, Acute myeloid leukemia
nutraceutical
Resveratrol
Stilbene with sirtuin/-related and anti-inflammatory reports in models. Pharmacokinetic limits and mixed trials caution against efficacy claims.
Mapped cancers: none yet
nutraceutical
Quercetin
Flavonol with -related and antioxidant in-vitro activity. Not a clinical oncology agent.
Mapped cancers: none yet
nutraceutical
Omega-3 fatty acids
EPA/DHA alter eicosanoid balance and membrane signalling. Cachexia and hypotheses exist; they are not cytotoxic oncology drugs.
Mapped cancers: Breast cancer, Colorectal cancer, MSI-high colorectal cancer, Hodgkin lymphoma
nutraceutical
Beta-glucans / medicinal-mushroom polysaccharides
β-glucans can engage Dectin-1 and complement pathways, modulating innate immunity in models and some adjunctive clinical settings. They are not tumour-selective cytotoxics.
Mapped cancers: MSI-high colorectal cancer, Hodgkin lymphoma
This oncology atlas is educational. Pathway maps, adjunctive strategies, and compound listings describe mechanistic relevance. They do not establish clinical efficacy, do not recommend treatment, and are not a substitute for oncology care. Evidence tiers are not equivalent.